Rossella Talotta1, Angela Berzi2, Fabiola Atzeni1, Alberto Batticciotto1, Mario Clerici3,4, Piercarlo Sarzi-Puttini1, Daria Trabattoni5. 1. Rheumatology Unit, Department of Internal Medicine, L. Sacco University Hospital, Milan, Italy. 2. L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Via GB Grassi 74, 20157, Milan, Italy. 3. Department of Physiopathology and Transplantation, University of Milan, Milan, Italy. 4. Don C. Gnocchi Foundation, IRCCS, Milan, Italy. 5. L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Via GB Grassi 74, 20157, Milan, Italy. daria.trabattoni@unimi.it.
Abstract
PURPOSE: The immunogenicity of anti-TNF-α drugs may affect their safety and efficacy. Infliximab (IFX), a chimeric monoclonal antibody, induces antibody formation in up to 60% of cases. Some studies have suggested the involvement of a Th1 response to TNFα blockers following immunization, but the triggering of Th17 responses has never been reported. The aim of this study is to investigate whether the immunogenicity of IFX affects the Th1, Th17 and Treg compartments in rheumatoid arthritis (RA) patients failing IFX therapy, and verify whether this may be responsible for treatment failure. METHODS: The study involved 55 patients with RA (15 treatment-naïve patients; 20 IFX responders; 20 IFX non-responders) and 10 healthy controls. PBMCs were cultured in the presence/absence of IFX, and the variations in the percentage of Th1, Th17 and Treg lymphocytes following IFX treatment were analysed. RESULTS: IFX-specific Th1 and Th17 responses and an increase in IL-21 production were observed in patients failing IFX (p < 0.01, p < 0.05, and p < 0.01 respectively). In contrast, IFX incubation reduced significantly Th1 and Th17 responses and IL-21 production (p < 0.05) in successfully-treated subjects, but did not affect these responses in healthy controls or treatment-naïve patients. CONCLUSIONS: RA patients may have impaired peripheral tolerance, which could favour the development of an aberrant immunological response to biological drugs. The loss of therapeutic effectiveness of IFX and the onset of adverse events may be due to a paradoxical activation of Th17 or Th1 lymphocytes following sensitisation, thus worsening the patients' inflammatory status.
PURPOSE: The immunogenicity of anti-TNF-α drugs may affect their safety and efficacy. Infliximab (IFX), a chimeric monoclonal antibody, induces antibody formation in up to 60% of cases. Some studies have suggested the involvement of a Th1 response to TNFα blockers following immunization, but the triggering of Th17 responses has never been reported. The aim of this study is to investigate whether the immunogenicity of IFX affects the Th1, Th17 and Treg compartments in rheumatoid arthritis (RA) patients failing IFX therapy, and verify whether this may be responsible for treatment failure. METHODS: The study involved 55 patients with RA (15 treatment-naïve patients; 20 IFX responders; 20 IFX non-responders) and 10 healthy controls. PBMCs were cultured in the presence/absence of IFX, and the variations in the percentage of Th1, Th17 and Treg lymphocytes following IFX treatment were analysed. RESULTS:IFX-specific Th1 and Th17 responses and an increase in IL-21 production were observed in patients failing IFX (p < 0.01, p < 0.05, and p < 0.01 respectively). In contrast, IFX incubation reduced significantly Th1 and Th17 responses and IL-21 production (p < 0.05) in successfully-treated subjects, but did not affect these responses in healthy controls or treatment-naïve patients. CONCLUSIONS:RApatients may have impaired peripheral tolerance, which could favour the development of an aberrant immunological response to biological drugs. The loss of therapeutic effectiveness of IFX and the onset of adverse events may be due to a paradoxical activation of Th17 or Th1 lymphocytes following sensitisation, thus worsening the patients' inflammatory status.
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: J P van Hamburg; P S Asmawidjaja; N Davelaar; A M C Mus; E M Colin; J M W Hazes; R J E M Dolhain; E Lubberts Journal: Arthritis Rheum Date: 2011-01
Authors: A Vultaggio; A Matucci; F Nencini; S Pratesi; P Parronchi; O Rossi; S Romagnani; E Maggi Journal: Allergy Date: 2009-11-27 Impact factor: 13.146
Authors: F Atzeni; R Talotta; F Salaffi; A Cassinotti; V Varisco; M Battellino; S Ardizzone; F Pace; P Sarzi-Puttini Journal: Autoimmun Rev Date: 2012-11-30 Impact factor: 9.754
Authors: Hong Nie; Yingxia Zheng; Runsheng Li; Taylor B Guo; Dongyi He; Lei Fang; Xuebin Liu; Lianbo Xiao; Xi Chen; Bing Wan; Y Eugene Chin; Jingwu Z Zhang Journal: Nat Med Date: 2013-02-10 Impact factor: 53.440
Authors: Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn Journal: World J Stem Cells Date: 2017-03-26 Impact factor: 5.326